Medication switch
Switching from Zepbound to Wegovy
tirzepatide → semaglutide — re-titration required
Tirzepatide → semaglutide — typically insurance, side effects, or cost-driven.
Medically reviewed by Dr. Jane Novak, MD, MPH on May 15, 2026
Cross-ingredient switch — re-titration required
Zepbound uses tirzepatide; Wegovy uses semaglutide. You restart from the starter dose and re-titrate over 12–20 weeks to reduce GI side effects.
Why patients make this switch
- 1Zepbound denied by insurance, Wegovy approved.
- 2Severe GI side effects on Zepbound — prescriber wants to try GLP-1 monotherapy.
- 3Patient on Wegovy savings card (Lilly card has different terms).
Dose transition
These medications use different active ingredients (semaglutide vs. tirzepatide). Re-titration from the starter dose is required to reduce GI side effects.
Timeline & titration
Re-titrate from Wegovy 0.25 mg through the standard 16-week schedule to reach 2.4 mg. Each dose holds 4 weeks. Total transition typically 16 weeks.
Side-effect transition
GI symptoms commonly return during re-titration. Patients on Zepbound 15 mg reaching only Wegovy 2.4 mg may notice some weight regain — Wegovy max dose is below Zepbound max.
Insurance & cost
When this switch is NOT recommended
- You are tolerating Zepbound well and meeting weight goals.
- You target weight loss above what semaglutide 2.4 mg typically delivers (~15% of baseline weight).
Switching to Wegovy? Book a telehealth visit.
Our ranked telehealth providers handle switching prescriptions, prior authorizations, and pharmacy coordination — typically 1–3 business days end to end.
See top providersEditorial ranking is independent of commission rates.
Frequently asked questions
Why would I switch from Zepbound to Wegovy?
Most common reasons: insurance prefers Wegovy, you experienced severe GI side effects on tirzepatide (possibly related to the GIP component), or the Wegovy savings card is more accessible. Clinically, expect somewhat less weight loss at the lower max dose.
Other switching guides
Reverse direction
Wegovy → Zepbound
Other from Zepbound
Zepbound → Mounjaro
Other from Zepbound
Zepbound → Ozempic
Other to Wegovy
Ozempic → Wegovy
Other to Wegovy
Mounjaro → Wegovy
Keep exploring
Resources for patients moving from Zepbound to Wegovy.
Drug overview
Wegovy — uses, dose, side effects
FDA-label overview of Wegovy (semaglutide) with dosing schedule and contraindications.
ReadDrug overview
Zepbound — full review
What you're switching from. Pricing, indications, and patient experience.
ReadLive data
FDA shortage tracker
Check current Wegovy availability and which doses are limited.
ReadFree tool
Are you a GLP-1 candidate?
Decision tree based on FDA criteria. Flags contraindications.
ReadFree tool
Prior auth letter generator
Draft a payer-ready PA letter your prescriber can sign in minutes.
ReadRanked & reviewed
Top GLP-1 providers for 2026
Telehealth providers ranked by price, ratings, and insurance.
Read
Common questions readers ask
- Does Ozempic cause hair loss?
- Not directly. Hair shedding (telogen effluvium) is reported by some patients ~3 months into rapid weight loss — typical of any rapid-weight-loss state, not unique to GLP-1. Full evidence-graded answer
- Can you drink alcohol on Wegovy?
- No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol — likely a secondary effect of GLP-1 on the brain reward system. Full evidence-graded answer
- Can I take GLP-1 while pregnant?
- No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life. Full evidence-graded answer
- How much does Wegovy cost without insurance?
- List price runs ~$1,350/mo at retail. NovoCare Pharmacy cash-pay direct from Novo Nordisk is $499/mo for all dose strengths. The Wegovy Savings Offer caps copay at $0-$225/mo for commercially insured patients depending on coverage status (not a flat $225 for everyone). Full evidence-graded answer
- Is it safe to take GLP-1 long-term?
- Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity. Full evidence-graded answer